Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15,357 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment Rationale and Design of a Phase III Study of Afatinib or Chemotherapy in Patients with Non-small-cell Lung Cancer Harboring Sensitizing Uncommon Epidermal Growth Factor Receptor Mutations (ACHILLES/TORG1834).
Miura S, Yamanaka T, Kato T, Ikeda S, Horinouchi H, Ichihara E, Kanazu M, Takiguchi Y, Tanaka K, Goto Y, Sata M, Hagiwara K, Okamoto H, Tanaka H. Miura S, et al. Among authors: tanaka k, tanaka h. Clin Lung Cancer. 2020 Nov;21(6):e592-e596. doi: 10.1016/j.cllc.2020.05.011. Epub 2020 May 21. Clin Lung Cancer. 2020. PMID: 32611505 Clinical Trial.
Phase I/II study of carboplatin plus weekly nab-paclitaxel in patients aged ≥75 years with squamous-cell lung cancer: TORG1322.
Zenke Y, Niho S, Umemura S, Ishihara M, Seki N, Nogami N, Hosomi Y, Shimokawa T, Tokito T, Goto Y, Miura Y, Saito H, Hida N, Ikeda S, Tanaka H, Furuya N, Misumi T, Yamanaka T, Ohe Y, Okamoto H. Zenke Y, et al. Among authors: tanaka h. Lung Cancer. 2020 Aug;146:182-188. doi: 10.1016/j.lungcan.2020.05.005. Epub 2020 May 19. Lung Cancer. 2020. PMID: 32559454 Clinical Trial.
Randomized phase II trial of S-1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancer.
Shimokawa T, Yamada K, Tanaka H, Kubota K, Takiguchi Y, Kishi K, Saito H, Hosomi Y, Kato T, Harada D, Otani S, Kasai T, Nakamura Y, Misumi T, Yamanaka T, Okamoto H. Shimokawa T, et al. Among authors: tanaka h. Cancer Med. 2021 Jan;10(2):626-633. doi: 10.1002/cam4.3641. Epub 2020 Dec 14. Cancer Med. 2021. PMID: 33319495 Free PMC article. Clinical Trial.
Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies.
Horinouchi H, Nishio M, Hida T, Nakagawa K, Sakai H, Nogami N, Atagi S, Takahashi T, Saka H, Takenoyama M, Katakami N, Tanaka H, Takeda K, Satouchi M, Isobe H, Maemondo M, Goto K, Hirashima T, Minato K, Sumiyoshi N, Tamura T. Horinouchi H, et al. Among authors: tanaka h. Cancer Med. 2019 Sep;8(11):5183-5193. doi: 10.1002/cam4.2411. Epub 2019 Jul 29. Cancer Med. 2019. PMID: 31353840 Free PMC article.
Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial.
Miyamoto S, Azuma K, Ishii H, Bessho A, Hosokawa S, Fukamatsu N, Kunitoh H, Ishii M, Tanaka H, Aono H, Nakahara Y, Kusaka K, Hosomi Y, Kikuchi N, Mori Y, Itani H, Hamada A, Yamada K, Okamoto H. Miyamoto S, et al. Among authors: tanaka h. JAMA Oncol. 2020 Jul 1;6(7):e201250. doi: 10.1001/jamaoncol.2020.1250. Epub 2020 Jul 9. JAMA Oncol. 2020. PMID: 32407455 Free PMC article. Clinical Trial.
Five-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: pooled analysis of the ONO-4538-05 and ONO-4538-06 studies.
Saka H, Nishio M, Hida T, Nakagawa K, Sakai H, Nogami N, Atagi S, Takahashi T, Horinouchi H, Takenoyama M, Katakami N, Tanaka H, Takeda K, Satouchi M, Isobe H, Maemondo M, Goto K, Hirashima T, Minato K, Yada N, Tamura T. Saka H, et al. Among authors: tanaka h. Jpn J Clin Oncol. 2021 Jan 1;51(1):106-113. doi: 10.1093/jjco/hyaa157. Jpn J Clin Oncol. 2021. PMID: 33020837 Free PMC article.
A Phase II Study to Assess the Efficacy of Osimertinib in Patients With EGFR Mutation-positive NSCLC Who Developed Isolated CNS Progression (T790M-negative or Unknown) During First- or Second-generation EGFR-TKI or Systemic Disease Progression (T790M-negative) After Treatment With First- or Second-generation EGFR-TKI and Platinum-based Chemotherapy (WJOG12819L).
Takeda M, Shimokawa M, Nakamura A, Nosaki K, Watanabe Y, Kato T, Hayakawa D, Tanaka H, Takahashi T, Kogure Y, Tachihara M, Fujimoto D, Yamaguchi K, Hamaguchi N, Okamoto I, Azuma K, Hasegawa K, Yamamoto N, Nakagawa K. Takeda M, et al. Among authors: tanaka h. Clin Lung Cancer. 2021 Jul;22(4):376-380. doi: 10.1016/j.cllc.2020.12.009. Epub 2021 Jan 25. Clin Lung Cancer. 2021. PMID: 33612406
A prospective phase II study of multimodal prophylactic treatment for afatinib-induced adverse events in advanced non-small cell lung cancer (Niigata Lung Cancer Treatment Group 1401).
Okajima M, Miura S, Watanabe S, Tanaka H, Ito K, Ishida T, Makino M, Iwashima A, Matsumoto N, Sato K, Ichikawa K, Abe T, Yoshizawa H, Kikuchi T. Okajima M, et al. Among authors: tanaka h. Transl Lung Cancer Res. 2021 Jan;10(1):252-260. doi: 10.21037/tlcr-20-649. Transl Lung Cancer Res. 2021. PMID: 33569309 Free PMC article.
Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study).
Seto T, Nosaki K, Shimokawa M, Toyozawa R, Sugawara S, Hayashi H, Murakami H, Kato T, Niho S, Saka H, Oki M, Yoshioka H, Okamoto I, Daga H, Azuma K, Tanaka H, Nishino K, Tohnai R, Yamamoto N, Nakagawa K. Seto T, et al. Among authors: tanaka h. J Immunother Cancer. 2022 Feb;10(2):e004025. doi: 10.1136/jitc-2021-004025. J Immunother Cancer. 2022. PMID: 35105689 Free PMC article. Clinical Trial.
15,357 results
You have reached the last available page of results. Please see the User Guide for more information.